BetaAbout 1.2% overall. As a group they ended with more shares than they started with. The biggest seller whose stake can be measured, Christopher Perry, sold shares equal to 8.2% of starting holdings, but more vested, so the stake grew.
| Who | Shares | Price | % of total stake | Total stake after | Trade date | Filed |
|---|---|---|---|---|---|---|
| Timothy Gokey CEO, Director | 16,982 | $161.15 | 9.6% | 159K | Oct 1, 2026 | Oct 5, 2026 |
| Christopher Perry President, Director | 4,752 | $161.15 | 8.8% | 49K | Oct 1, 2026 | Oct 5, 2026 |
| Richard Stingi Corporate VP and CHRO | 1,109 | $161.15 | 14% | 6.6K | Oct 1, 2026 | Oct 5, 2026 |
| Douglas Deschutter Co-President ICS | 911 | $161.15 | 5.0% | 17K | Oct 1, 2026 | Oct 5, 2026 |
| Ashima Ghei CFO | 315 | $161.15 | 4.9% | 6.1K | Oct 1, 2026 | Oct 5, 2026 |
"% of total stake" is the shares in this event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings don't reconcile, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.
| Who | Shares | Price | % of total stake | Total stake after | Trade date | Filed |
|---|---|---|---|---|---|---|
| Thomas Carey Corporate VP | 2,501 | $159.76 | 22% | 8.8K | Oct 1, 2026 | Oct 5, 2026 |
"% of total stake" is the shares in this event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings don't reconcile, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.
Percentages cover 14 of 16 officers and directors. Left out: Thomas Carey and Hope Jarkowski (most of their shares vested during the period, so a percentage would mislead). Disclosed company stock is not an insider's whole wealth.
Officers and directors, past 12 months. Each bar is 100% of that person's own stake; not comparable between people. The stake is the vested shares held at the start of the period (Oct 9, 2025); the gold part is what they sold.
Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.
No. Timothy Gokey reported no open-market sales in the past 12 months.
Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 0% of sales by value ran under 10b5-1 trading plans disclosed in the filings, 10% were to cover taxes and 90% had no disclosed plan. A trading plan schedules sales in advance.
Yes. 1 officer or director reported 1 purchase in the past 12 months (Form 4 code P, which includes private purchases).
About 1.2% overall. As a group they ended with more shares than they started with. The biggest seller whose stake can be measured, Christopher Perry, sold shares equal to 8.2% of starting holdings, but more vested, so the stake grew. That covers the 12 months to Oct 9, 2026 and counts vested shares reported on SEC Forms 3, 4 and 5, which is not an insider's whole wealth.
| Who sold | Amount | % of holdings | Trading plan |
|---|---|---|---|
| Thomas Carey Corporate VP | $2.7M 13K shares | 59%†i† Most of the shares Thomas Carey sold arrived during the period, so this is shares sold as a share of the 6.1K held at the start plus the 15K received, less 0 withheld by the company for taxes. | 15% to cover taxes 85% no plan disclosed |
| Christopher Perry President, Director | $900K 4K shares | 8.2% | No plan disclosed |
| Hope Jarkowski Chief Legal Officer | $305K 2K shares | 99.9%†i† Most of the shares Hope Jarkowski sold arrived during the period, so this is shares sold as a share of the 1 held at the start plus the 2.9K received, less 913 withheld by the company for taxes. | No plan disclosed |
| Robert Duelks Director | $49K 253 shares | 0.5% | No plan disclosed |
Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.
| Insider | Held Oct 9, 2025 | Sold | Held Oct 9, 2026 | Still held | ||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Timothy Gokey CEO, Director | 143K | 0 | 159K | no sales | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Timothy Gokey0shares vested or exercised −5.7Kgifted (net of own trusts) −17Kwithheld by the company for taxes none reportedunvested awards, start → end Stock options (not counted as shares):
Estimate: options held × ($159.76 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||
Robert DuelksiMinor difference of -253 shares. Difference is under 0.5% of holdings. Director | 51K | −253 | 51K | 100.0% | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Robert Duelks0shares vested or exercised 0gifted (net of own trusts) none reportedunvested awards, start → end
Stock options (not counted as shares):
Estimate: options held × ($159.76 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. Reconciliation: minor difference of -253 shares. Difference is under 0.5% of holdings. | ||||||||||||||||||||||||||||||||||||||||||||
| Christopher Perry President, Director | 49K | −4K | 49K | +1.2% | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Christopher Perry0shares vested or exercised 0gifted (net of own trusts) −4.8Kwithheld by the company for taxes none reportedunvested awards, start → end Stock options (not counted as shares):
Estimate: options held × ($159.76 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||
| Maura Markus Director | 31K | 0 | 33K | no sales | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Maura Markus0shares vested or exercised 0gifted (net of own trusts) none reportedunvested awards, start → end Stock options (not counted as shares):
Estimate: options held × ($159.76 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||
| Douglas Deschutter Co-President ICS | 16K | 0 | 17K | no sales | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Douglas Deschutter0shares vested or exercised 0gifted (net of own trusts) −911withheld by the company for taxes none reportedunvested awards, start → end Stock options (not counted as shares):
Estimate: options held × ($159.76 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||
| brett keller Director | 16K | 0 | 17K | no sales | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for brett keller0shares vested or exercised 0gifted (net of own trusts) none reportedunvested awards, start → end Stock options (not counted as shares):
Estimate: options held × ($159.76 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||
| Annette Nazareth Director | 8.5K | 0 | 9.8K | no sales | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Annette Nazareth0shares vested or exercised 0gifted (net of own trusts) none reportedunvested awards, start → end Stock options (not counted as shares):
Estimate: options held × ($159.76 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||
| Amit Zavery Director | 7.9K | 0 | 9.3K | no sales | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Amit Zavery0shares vested or exercised 0gifted (net of own trusts) none reportedunvested awards, start → end Stock options (not counted as shares):
Estimate: options held × ($159.76 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||
| Pamela Carter Director | 7.3K | 0 | 7.3K | no sales | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Pamela Carter0shares vested or exercised 0gifted (net of own trusts) none reportedunvested awards, start → end Stock options (not counted as shares):
Estimate: options held × ($159.76 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||
Thomas CareyiIncludes unvested RSUs, amount not disclosed. Corporate VP | 6.1K | −13K | 8.8K | not meaningful | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Thomas Carey+10Kshares vested or exercised 0gifted (net of own trusts) none reportedunvested awards, start → end
Stock options (not counted as shares):
Estimate: options held × ($159.76 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||
Richard StingiiIncludes unvested RSUs, amount not disclosed. Corporate VP and CHRO | 5.5K | 0 | 6.6K | no sales | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Richard Stingi0shares vested or exercised 0gifted (net of own trusts) −1.1Kwithheld by the company for taxes none reportedunvested awards, start → end
Stock options (not counted as shares):
Estimate: options held × ($159.76 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||
| Ashima Ghei CFO | 4K | 0 | 6.1K | no sales | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Ashima Ghei+2.9Kshares vested or exercised 0gifted (net of own trusts) −1.2Kwithheld by the company for taxes 2.9K → 0unvested awards, start → end Stock options (not counted as shares):
Estimate: options held × ($159.76 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||
| Eileen Murray Director | 3.7K | 0 | 6.2K | no sales | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Eileen Murray0shares vested or exercised 0gifted (net of own trusts) none reportedunvested awards, start → end Stock options (not counted as shares):
Estimate: options held × ($159.76 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||
| Melvin Flowers Director | 2.2K | 0 | 2.7K | no sales | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Melvin Flowers0shares vested or exercised 0gifted (net of own trusts) none reportedunvested awards, start → end Stock options (not counted as shares):
Estimate: options held × ($159.76 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||
Patricia MosconiiStarted reporting during the period; starting holdings are from the Form 3. Director | 10 | 0 | 824 | no sales | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Patricia Mosconi0shares vested or exercised 0gifted (net of own trusts) none reportedunvested awards, start → end
Stock options (not counted as shares):
Estimate: options held × ($159.76 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||
| Hope Jarkowski Chief Legal Officer | 1 | −2K | 1 | not meaningful | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Hope Jarkowski+2.9Kshares vested or exercised 0gifted (net of own trusts) −913withheld by the company for taxes 3.9K → 1Kunvested awards, start → end Stock options (not counted as shares):
Estimate: options held × ($159.76 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||
16 of 16 insiders fully reconciled: starting holdings plus reported transactions match ending holdings (15 exactly, 1 with a minor or footnoted difference). Percentages cover 14 of 16 officers and directors. Left out: Thomas Carey and Hope Jarkowski (most of their shares vested during the period, so a percentage would mislead). "Still held" compares ending with starting vested shares; a plus sign means the holding grew.
Officer and director open-market sales: $4.0M across 18,918 shares. Plan status and stated purpose are separate questions, and a sale can have both.
Sales with no 10b5-1 plan and no tax reference in the filing. $2.3M of it is Thomas Carey. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Thomas Carey, Dec 3, 2025
$400K of sales (10.0%) cite tax obligations in their footnotes. Separately, 25,887 shares ($4.1M) were withheld by the company for taxes, which isn't a market sale. Example: Thomas Carey, Oct 1, 2026
1 officer or director bought shares in this period, in 1 trade(Form 4 code P). Across all their filings on record there are 6 purchase trades.
Gifts the filings describe as charitable. Gifts are not sales and are not included in the sale totals.
| Seller | Shares sold | Proceeds | Under a disclosed plan | Share of total | Sales dates |
|---|---|---|---|---|---|
| Thomas Carey Corporate VP | 13K | $2.7M | 0% | 69% | Dec 3, 2025 to Oct 1, 2026 |
| Christopher Perry President, Director | 4K | $900K | 0% | 23% | Nov 18, 2025 to Nov 18, 2025 |
| Hope Jarkowski Chief Legal Officer | 2K | $305K | 0% | 8% | Jun 4, 2026 to Jun 4, 2026 |
| Robert Duelks Director | 253 | $49K | 0% | 1% | Feb 6, 2026 to Feb 6, 2026 |
| Month | Sale proceeds | Disclosed plan | To cover taxes | No plan disclosed |
|---|---|---|---|---|
| Oct 2025 | $0 | $0 | $0 | $0 |
| Nov 2025 | $900K | $0 | $0 | $900K |
| Dec 2025 | $2.3M | $0 | $0 | $2.3M |
| Jan 2026 | $0 | $0 | $0 | $0 |
| Feb 2026 | $49K | $0 | $0 | $49K |
| Mar 2026 | $0 | $0 | $0 | $0 |
| Apr 2026 | $0 | $0 | $0 | $0 |
| May 2026 | $0 | $0 | $0 | $0 |
| Jun 2026 | $305K | $0 | $0 | $305K |
| Jul 2026 | $0 | $0 | $0 | $0 |
| Aug 2026 | $0 | $0 | $0 | $0 |
| Sep 2026 | $0 | $0 | $0 | $0 |
| Oct 2026 | $400K | $0 | $400K | $0 |
Less than usual: about one-twentieth of the 5-year average. 4 insiders sold; the average is 11 a year.
| 12 months ending | Shares sold | Insiders who sold | Proceeds |
|---|---|---|---|
| Oct 9, 2026 Latest 12 months | 19K | 4 | $4.0M |
| Oct 9, 2025 1 year earlier | 385K | 11 | $94.1M |
| Oct 9, 2024 2 years earlier | 250K | 9 | $50.6M |
| Oct 10, 2023 3 years earlier | 362K | 13 | $62.7M |
| Oct 10, 2022 4 years earlier | 288K | 9 | $50.9M |
| Oct 10, 2021 5 years earlier | 524K | 12 | $85.0M |
Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.
Every officer and director reconciles for this period.
Robert Duelks: minor difference of -253 shares. Difference is under 0.5% of holdings.
External context: we only cite outside events when a documented connection exists. None is shown for this period.
All 2,134 Forms 3, 4 and 5 filed for Broadridge Financial Solutions (SEC CIK 1383312) from Apr 4, 2007 to Oct 6, 2026, retrieved from SEC EDGAR on Oct 9, 2026. Prices are the ones reported in each filing, often weighted averages.
Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.
Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".
Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.